|
Telik, Inc. of Palo Alto, CA is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced investigational drug candidates in clinical development are TELINTRA® (Ezatiostat HCl, TLK199) for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA® (Canfosfamide HCl, TLK286) for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP™, which enables the rapid and efficient discovery of small molecule drug candidates.
 Telik Earnings Call
Thursday, May 8, 2008
4:30 pm Eastern (1:30 pm Pacific)
Click here for the webcast.
April 9, 2008
The Wall Street Transcript Interview with Dr. Michael Wick and Cynthia Butitta
March 7, 2008
CEOCFO Interview with Dr. Michael Wick and Cynthia Butitta
May 1, 2008
Telik Announces 2008 First Quarter Financial Release, Conference Call and Webcast
April 17, 2008
Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
|
